ENOVIS CORP (ENOV) Stock Fundamental Analysis
USA - NYSE:ENOV - US1940141062 - Common Stock
31.72 USD
+0.14 (+0.44%)
33 USD
+1.28 (+4.04%)
Taking everything into account, ENOV scores 4 out of 10 in our fundamental rating. ENOV was compared to 191 industry peers in the Health Care Equipment & Supplies industry. ENOV has a bad profitability rating. Also its financial health evaluation is rather negative. ENOV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
In the past year ENOV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
ENOV had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
ENOV has a Return On Assets (-16.48%) which is comparable to the rest of the industry.
ENOV's Return On Equity of -32.10% is in line compared to the rest of the industry. ENOV outperforms 55.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROIC | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ENOV's Operating Margin has declined in the last couple of years.
ENOV has a Gross Margin (56.32%) which is comparable to the rest of the industry.
ENOV's Gross Margin has improved in the last couple of years.
ENOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ENOV has more shares outstanding
Compared to 5 years ago, ENOV has more shares outstanding
The debt/assets ratio for ENOV is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.94, we must say that ENOV is in the distress zone and has some risk of bankruptcy.
ENOV's Altman-Z score of 0.94 is in line compared to the rest of the industry. ENOV outperforms 52.88% of its industry peers.
A Debt/Equity ratio of 0.53 indicates that ENOV is somewhat dependend on debt financing.
The Debt to Equity ratio of ENOV (0.53) is worse than 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.94 |
ROIC/WACCN/A
WACC7.33%
2.3 Liquidity
ENOV has a Current Ratio of 2.25. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
ENOV has a Current ratio of 2.25. This is comparable to the rest of the industry: ENOV outperforms 43.46% of its industry peers.
A Quick Ratio of 1.15 indicates that ENOV should not have too much problems paying its short term obligations.
ENOV's Quick ratio of 1.15 is on the low side compared to the rest of the industry. ENOV is outperformed by 69.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 34.01% over the past year.
The earnings per share for ENOV have been decreasing by -16.18% on average. This is quite bad
ENOV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.40%.
The Revenue has been decreasing by -8.73% on average over the past years.
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
3.2 Future
Based on estimates for the next years, ENOV will show a very strong growth in Earnings Per Share. The EPS will grow by 23.19% on average per year.
ENOV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.87% yearly.
EPS Next Y12.61%
EPS Next 2Y11.83%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.58, the valuation of ENOV can be described as reasonable.
Based on the Price/Earnings ratio, ENOV is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.30, ENOV is valued rather cheaply.
With a Price/Forward Earnings ratio of 8.96, the valuation of ENOV can be described as very reasonable.
94.24% of the companies in the same industry are more expensive than ENOV, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, ENOV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.58 | ||
| Fwd PE | 8.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ENOV is valued cheaper than 87.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.18 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ENOV's earnings are expected to grow with 13.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y11.83%
EPS Next 3Y13.12%
5. Dividend
5.1 Amount
ENOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
31.72
+0.14 (+0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners106.87%
Inst Owner Change5.05%
Ins Owners1.16%
Ins Owner Change7.89%
Market Cap1.81B
Analysts83.53
Price Target55.42 (74.72%)
Short Float %11.81%
Short Ratio4.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.28%
Min EPS beat(2)6.8%
Max EPS beat(2)7.76%
EPS beat(4)4
Avg EPS beat(4)8.94%
Min EPS beat(4)4.97%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)5.78%
EPS beat(12)12
Avg EPS beat(12)8.75%
EPS beat(16)15
Avg EPS beat(16)7.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.21%
Revenue beat(4)0
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.21%
Revenue beat(8)2
Avg Revenue beat(8)-0.97%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-8.66%
PT rev (1m)-7.03%
PT rev (3m)-7.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.5%
EPS NY rev (1m)2.91%
EPS NY rev (3m)2.06%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.64%
Revenue NY rev (1m)0.83%
Revenue NY rev (3m)0.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.58 | ||
| Fwd PE | 8.96 | ||
| P/S | 0.83 | ||
| P/FCF | N/A | ||
| P/OCF | 9.64 | ||
| P/B | 0.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.18 |
EPS(TTM)3.31
EY10.44%
EPS(NY)3.54
Fwd EY11.16%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)3.29
OCFY10.37%
SpS38.31
BVpS45.1
TBVpS-9.54
PEG (NY)0.76
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.48% | ||
| ROE | -32.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.32% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 66.53% | ||
| Cap/Sales | 8.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 66.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.25 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 0.94 |
F-Score3
WACC7.33%
ROIC/WACCN/A
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.01%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%27.42%
EPS Next Y12.61%
EPS Next 2Y11.83%
EPS Next 3Y13.12%
EPS Next 5Y23.19%
Revenue 1Y (TTM)14.4%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%7.5%
Revenue Next Year7.28%
Revenue Next 2Y6.83%
Revenue Next 3Y6.79%
Revenue Next 5Y8.87%
EBIT growth 1Y-155.23%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year71.62%
EBIT Next 3Y30.39%
EBIT Next 5Y28.11%
FCF growth 1Y96.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y889.17%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%